Dactolisib (BEZ235) is a dual inhibitor of PI3K and mTOR that can downregulate the AKT-mTOR-HIF1α signaling pathway, inhibiting tumor-induced angiogenesis and promoting cell death through apoptotic pathways. Here, PIK3CD is linked to neoplasm.